It’s Increasingly Clear That MFN Will Impact Europe First

And the votes are in on the “healthcare” vs “health care” debate ...

Regeneron’s Free Gene Therapy, Six New Meds to TrumpRx (and One to Mark Cuban), and the Ten Other Stories to Track Today

And I need your vote on an issue of huge significance

APEX Special Edition: 340B Is Having a Week. These 10 Stories Prove It.

The Three Most Interesting Things RFK Jr. Said About Drug Prices This Week

And we know that CMS will pay for obesity meds in Medicare through 2027. But what about 2028 ... and beyond?

Having Lost Its BALANCE, CMS Is Now Walking Across a ‘Bridge’ To Obesity Coverage in Medicare

And BMS’ pricing transparency data is out, showing that net prices continue to fall

Off-BALANCE: The Effort to Bring Obesity Meds Into Medicare Hits a Snag as Major Payers Express Doubts

And United had a blowout earnings release. Its PBM, Optum Rx? Not so much.

It’s Decision Day for Health Plans: Will They Opt to Cover Obesity Meds in Medicare?

And more evidence that prior authorization decisions are often delayed

Medicare Coverage of Obesity Drugs Hangs in the BALANCE

I'm looking for your vote on whether the CMS pilot will move forward

Bernie and RFK Jr. Are Making Noise on the Hill Today. Don’t Feel Compelled to Listen.

And a sampling of the comments on a Labor Department proposal to rein in PBMs

Listing the New Additions to TrumpRx, From Least Surprising to Most Eyebrow-Raising

And the majority of new prescriptions written get rejected by commercial plans, IQVIA analysis finds

A Spring Reading List of Essential Research and Analyses

CMS Targets Prior Auth Timelines for Medicines, Though High Denial Rates May Be the Bigger Issue

And BIO’s leader expresses concern about the MFN choices smaller biotechs must make

A New Poll Underscores Patient Interest – and Payer Risk – in Medicare Coverage of GLP-1s for Obesity

AbbVie Launches a New Legal Battle Over 340B, Challenging the Government Definition of ‘Patient’

AbbVie Launches a New Legal Battle Over 340B, Challenging the Government Definition of ‘Patient’

PCMA Survey Says Employers Love Their PBMs. But There Are Reasons to Be Skeptical.

A New Analysis Makes Clear How Expensive It Will Be for Plans to Add Obesity Meds to Medicare

Plus, the crossover event of the year: TrumpRx is driving traffic to Mark Cuban Cost Plus Drugs

Looking Past the Tariff Headlines to Focus on Where the Impact Is ... and Is Not

And the White House budget proposal includes a huge boost in funding to oversee 340B

Lilly Wins FDA Approval for Its Foundayo Obesity Pill, Which Will Cost Between $149 and $349

Plus the drug industry gets a big appeals court win in the ongoing battle to set rules around 340B contract pharmacies

Drugmakers Aren’t Buying What the White House Is Selling on MFN

And a price war of sorts is emerging as Arrowhead and Ionis prepare to enter a large CV disease market

On a Busy Day for Pricing and Policy News, Here Are the Top 10 Stories

Vanda’s New Schizophrenia Drug Offers the Company a Way Out of Medicaid Inflation Penalties

And a new paper makes clear how quickly Chinese biopharma has risen

Yesterday Brought Two New Drug Approvals ... and Two Pricing Announcements

That’s notable, because, before yesterday, prices had not been publicly disclosed for a single med approved in 2026

The Impact of MFN, Especially Overseas, Remains Cloudy

And a legal case that seeks to close the 340B “STD loophole” kicks off

Introducing the TrumpRx Tracker